These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23012621)

  • 1. Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
    Rath BA; Olshen RA; Halpern J; Merigan TC
    Viruses; 2012 Aug; 4(8):1212-34. PubMed ID: 23012621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
    Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.
    Hoffmann D; Garcia AD; Harrigan PR; Johnston IC; Nakasone T; García-Lerma JG; Heneine W
    PLoS One; 2011; 6(7):e22019. PubMed ID: 21799767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
    Wainberg MA; Hsu M; Gu Z; Borkow G; Parniak MA
    AIDS; 1996 Dec; 10 Suppl 5():S3-10. PubMed ID: 9030390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
    Svicher V; Alteri C; Artese A; Forbici F; Santoro MM; Schols D; Van Laethem K; Alcaro S; Costa G; Tommasi C; Zaccarelli M; Narciso P; Antinori A; Ceccherini-Silberstein F; Balzarini J; Perno CF
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):336-44. PubMed ID: 20739898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
    Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
    Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
    McIntyre JA; Hopley M; Moodley D; Eklund M; Gray GE; Hall DB; Robinson P; Mayers D; Martinson NA
    PLoS Med; 2009 Oct; 6(10):e1000172. PubMed ID: 19859531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
    Rajesh L; Karunaianantham R; Narayanan PR; Swaminathan S
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1179-85. PubMed ID: 19895208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).
    García Lerma J; Schinazi RF; Juodawlkis AS; Soriano V; Lin Y; Tatti K; Rimland D; Folks TM; Heneine W
    Antimicrob Agents Chemother; 1999 Feb; 43(2):264-70. PubMed ID: 9925516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
    Hauser A; Sewangi J; Mbezi P; Dugange F; Lau I; Ziske J; Theuring S; Kuecherer C; Harms G; Kunz A
    PLoS One; 2012; 7(2):e32055. PubMed ID: 22384138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.
    Jonckheere H; Witvrouw M; De Clercq E; Anné J
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):249-53. PubMed ID: 9491915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
    Kamya MR; Mayanja-Kizza H; Kambugu A; Bakeera-Kitaka S; Semitala F; Mwebaze-Songa P; Castelnuovo B; Schaefer P; Spacek LA; Gasasira AF; Katabira E; Colebunders R; Quinn TC; Ronald A; Thomas DL; Kekitiinwa A;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):187-93. PubMed ID: 17693883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
    McMahon DK; Zheng L; Hitti J; Chan ES; Halvas EK; Hong F; Kabanda J; Taulo F; Kumarasamy N; Bonhomme J; Wallis CL; Klingman KL; Hughes MD; Mellors JW
    Clin Infect Dis; 2013 Apr; 56(7):1044-51. PubMed ID: 23300238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
    Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
    AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.